Table 1.
Subject demographics and disease characteristics among the N = 129 subjects involved in this study
| Subject subgroup | ||
| HIV-infected controls | 30 | (23%) |
| HIV-infected impaired subjects | 99 | (77%) |
| Placebo | 48 | (37%) |
| Memantine | 51 | (40%) |
| Age at baseline (years) | ||
| Median (IQR) | 42 | (36–46) |
| HIV RNA, plasma (log10 copies/mL) | ||
| Median (IQR) | 2.2 | (<50–4.2) |
| HIV RNA, CSF (log10 copies/mL) | ||
| Median (IQR) | <50 | (<50–2.5) |
| CD4+ cell count (cells/μL) | ||
| Median (IQR) | 274 | (168–428) |
| Gender (male) | ||
| N (%) | 115 | (89%) |
| Ethnicity (% white) | 88 | (68%) |
| Antiretroviral use | ||
| N (%) | 118 | (91%) |
| ADC stage | ||
| Normal (stage 0) | 30 | (23%) |
| Subclinical (stage 1) | 83 | (64%) |
| Stage 2 | 14 | (11%) |
| Stage 3 | 2 | (2%) |